Back to Schemes

Homologous Recombination Deficiency (HRD) testing in ovarian cancer [Tissue]

Product Code: HRD-25

From £285.00

Registration closed: 28/02/2025

Applicable to all labs undertaking molecular genetic testing for HRD in solid tumours.

Target/Genes:

Testing for HRD status in ovarian tumours

Technology:

Any molecular test, CNV, MLPA, NGS, Panel testing, Sanger sequencing

Language:

English

Sample Type:

FFPE (real human tumour tissue and artificial materials)

Accredited:

No

EQA Assessment

The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.

Participants will receive an individual report including educational advice and a scheme summary report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics which allow participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Sample Details

Three mock clinical cases with matching samples will be provided.

Two 10µm FFPE sections per case are provided.

Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.

EQA Results

Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.

Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.

Participation Information

Restricted to 100 participants, please register early to avoid disappointment. Open to laboratories from ALL countries (note: some restrictions may apply*)

This EQA is supported by an educational grant from AstraZeneca and MSD, fees are subsidised so there is a reduced cost for participants. The EQA providers acknowledge and thank AstraZeneca and MSD for this support.

*Sanctions, delivery network exceptions, restrictions on importation etc.

How it works

Register

  • Enrol before the closing date
  • EMQN ships EQA samples or digital cases

Test & submit results

  • Analyse samples in your routine workflow
  • Upload results via QA Manager

Review & get certified

  • EMQN benchmarks your data
  • Receive final report & Certificate of Participation

Enquire about this scheme

Contact Information

added wishlist!
View Wishlist

0

View Wishlist

Register Interest

Express your interest in ''.